You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 26, 2024

Claims for Patent: 7,208,288


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 7,208,288
Title:Methods for enhancing the lysis of coagulated blood with apolipoprotein E2 phenotype
Abstract: Methods for enhancing the lysis of coagulated blood comprise administering to coagulated blood a combination of clot clysis agent and a lysis enhancing amount of apolipoprotein E2 (Apo E2) or a therapeutic derivative thereof. Methods for reducing the risk of blood coagulation comprise administering to blood a combination of a clot lysis agent and a lysis enhancing amount of Apo E2 or a therapeutic derivative thereof. Additional methods for enhancing the lysis of coagulated blood comprise administering to an individual a specific level of clot lysis agent wherein the specific level is based upon the apolipoprotein phenotype of the individual. Further methods for reducing the risks of blood coagulation comprise administering to blood a specific level of a clot lysis agent wherein the specific level is based upon the apolipoprotein phenotype of the individual.
Inventor(s): Broderick; Joseph P. (Cincinnati, OH), Clark; Joseph F. (Cincinnati, OH), Woo; Daniel (Cincinnati, OH)
Assignee:
Application Number:10/398,880
Patent Claims:1. A method for enhancing lysis of coagulated blood, comprising administering to coagulated blood a combination of a clot lysis agent and a lysis-enhancing amount of apolipoprotein E2 (Apo E2) or a therapeutic derivative thereof.

2. The method as defined by claim 1, wherein the clot lysis agent comprises tissue plasminogen activator (t-PA).

3. The method as defined by claim 1, wherein the clot lysis agent comprises a t-PA derivative.

4. The method as defined by claim 1, wherein a therapeutic derivative comprising fragments of Apo E2 having lysis-enhancing activity is administered.

5. The method as defined by claim 1, wherein the clot lysis agent comprises TNK-t-PA, t-PA, reteplase, streptokinase, heparin, coumadin, GIIb IIIa receptor blockers, therapeutic derivatives thereof, or mixtures thereof.

6. The method as defined by claim 1, wherein the clot lysis agent and the lysis-enhancing amount of Apo E2 are administered to reduce an individual's elevated level of coagulated blood.

7. The method as defined by claim 1, wherein the clot lysis agent and the lysis-enhancing amount of Apo E2 are administered to an individual with an ischemic disease.

8. The method as defined by claim 7, wherein the ischemic disease comprises myocardial infarction, unstable angina, coronary artery thrombus, or peripheral vascular disease.

9. The method as defined by claim 8, wherein the peripheral vascular disease comprises occlusion, retinopathy, or organ embolism.

10. The method as defined by claim 9, wherein the organ embolism comprises pulmonary embolism.

11. The method as defined by claim 1, wherein the clot lysis agent and the lysis-enhancing amount of Apo E2 are administered to an individual with post surgical complications of occlusion or clotting.

12. A method of reducing the risk of blood coagulation, comprising administering to blood a combination of a clot lysis agent and a lysis-enhancing amount of Apo E2 or a therapeutic derivative thereof.

13. The method as defined by claim 12, wherein the combination is administered to reduce the risk of the formation of an angiographic catheter clot.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.